The Ibrance Simulator is a Promotion resource, used by Pfizer Oncology Healthcare Development Managers, that will be used in Ibrance Promotional conversations.
Discrete event simulation is an effective form of scenario generation and engagement around service transformation for healthcare. It can be used to model hospital departments, pathways or entire health economies in an animated and compelling manner.
Simulations are communication tools. They open debate, they enable conversations and engender close working with hospitals and wider healthcare commissioning towards all round healthcare improvements.
The objective of the Ibrance simulation model is to demonstrate, to NHS stakeholders, the benefits of adopting Ibrance for the treatment of ER +ve, HER2 -ve patients with advanced breast cancer in the following key points:
Firstly the freeing of capacity in the chemotherapy clinic and cost savings by adopting Ibrance to delay disease progression and chemotherapy treatment.
Secondly, further Service optimisation by moving away from a consultant led or secondary care led service where appropriate.
The results from all scenarios can be exported into a results summary and, on request, the Results Summary Document and Data Analytics resource, can be provided to Healthcare Professions (HCPs) directly from the resource.
HowcouldIBRANCE make a difference to your service capacity and Optimisation ?
Ever wondered how you can discuss smoking cessation in a COPD consultation? Or what does a brief consultation on smoking cessation look like? These webinars bring solutions to these two challenges, to life.
This 3 minute animation video which provides an overview of the PALOMA-1 trial consisting of information such as study design, efficacy and quality of life (QoL). Once you have viewed the video and if you require further information please select the relevant tabs.
Should we be reflex-ROS1 testing on ALL lung cancer patients? Professor Nicholson gives his professional opinion on this question and others including tips for laboratories who want to validate their own ROS1 testing service.
Dr Neal Navani answers the key question: What is the importance of optimal tissue acquisition in lung cancer patients? and gives his recommendations on optimal sample acquisition.
Dr Tim Benepal describes his vision of the optimal testing model for molecular testing by answering two significant questions: Should all molecular testing be carried out in-house? And when in a patient’s diagnostic pathway should these tests be requested?
"By clicking "confirm" to create an account, you confirm that the information you have provided above is correct, and you agree to (i) Pfizer’s processing of your personal data, including its transfer internationally and to third parties, in accordance with the Pfizer Privacy and Cookie Policy; and (ii) Pfizer’s Website Terms of Use."
